000 | 01765cam a2200349 a 4500 | ||
---|---|---|---|
003 | EG-GiCUC | ||
005 | 20250223030901.0 | ||
008 | 131102s2013 ua f m 000 0 eng d | ||
040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
041 | 0 | _aeng | |
049 | _aDeposite | ||
097 | _aPh.D | ||
099 | _aCai01.11.33.Ph.D.2013.Ha.F | ||
100 | 0 | _aHaitham Ahmed Ali Gabr | |
245 | 1 | 0 |
_aFluvastatin as an adjuvant therapy with pegylated interferon and ribavirin in the treatment of chronic hepatitis C virus / _cHaitham Ahmed Ali Gabr ; Supervised Zakaria A. Salama , Moataz Serry Seyam , Ahmed Fouad Soliman |
246 | 1 | 5 | _aالفلوفاستاتين كعقار مساعد لعقاري الانترفيرون طويل المفعول و الريبافيرين فى علاج الالتهاب الكبدى الوبائى الفيروسي (سى) المزمن |
260 |
_aCairo : _bHaitham Ahmed Ali Gabr , _c2013 |
||
300 |
_a288 P. ; _c25cm |
||
502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine | ||
520 | _aIt could be argued that statins, besides a weak direct antiviral effect, may enhance HCV infectivity of hepatocytes through the decrease in circulating LDL levels and the up-regulation of LDL receptors. This effect of statins might counterbalance the antiviral activity described in the replicon models | ||
530 | _aIssued also as CD | ||
653 | 4 | _aFluvastatin | |
653 | 4 | _aStatins and HCV | |
653 | 4 | _aTreatment of HCV | |
700 | 0 |
_aAhmed Fouad Soliman , _eSupervisor |
|
700 | 0 |
_aMoataz Serry Seyam , _eSupervisor |
|
700 | 0 |
_aZakaria Abdellateef Salama , _eSupervisor |
|
856 | _uhttp://172.23.153.220/th.pdf | ||
905 |
_aNazla _eRevisor |
||
905 |
_aSamia _eCataloger |
||
942 |
_2ddc _cTH |
||
999 |
_c43962 _d43962 |